Skip to main content
Top
Published in: Neurological Sciences 5/2016

01-05-2016 | Original Article

A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson’s disease

Authors: Hui-Qing Zhao, Fang-fei Li, Zhan Wang, Xue-Mei Wang, Tao Feng

Published in: Neurological Sciences | Issue 5/2016

Login to get access

Abstract

In the present study, we detected the level of oligomeric form of α-synuclein in the red blood cells of ischemic stroke, Parkinson’s disease, and normal people and compared the differences to assess the diagnosis potential of α-synuclein in ischemic stroke patients. 86 ischemic stroke, 100 PD, and 102 healthy cases were enrolled in the present study. Total protein amount in the red blood cells were quantified by BCA assay using spectrophotometer. Levels of oligomeric form of α-synuclein were characterized by a sandwich ELISA. Analysis of correlation analysis and receiver operating characteristic curve were conducted. Significant differences were detected in the levels of oligomeric forms of α-synuclein in different samples’ blood cells (P < 0.05); the levels of total protein in (188.1 ± 33.9 mmol/L) healthy people were significantly higher than that of PD (147.7 ± 45.0 mmol/L) and ischemic stroke groups (142.9 ± 43.0 mmol/L) (P < 0.05). There was no correlation between the age of patients and level of α-synuclein (R 2 = 0.216 in ischemic stroke group and −0.104 in PD group) and the receiver operating characteristic curve analysis showed a high sensitivity of α-synuclein in discriminating ischemic stroke (sensitivity was 63.7 % and specificity was 9.6 %) and PD (sensitivity was 44.1 % and specificity was 12.5 %) patients from the controls. The levels of oligomeric form of α-synuclein of red blood cells in ischemic stroke and Parkinson’s disease patients were both significant higher than normal people. And the level of oligomeric form α-synuclein showed a potential for diagnosis of ischemic stroke in clinic.
Literature
1.
go back to reference Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F, Ragonese P, Patti F, Reggio A, Di Perri R, Savettieri G (2000) Parkinson disease survival: a population-based study. Arch Neurol 57(4):507–512CrossRefPubMed Morgante L, Salemi G, Meneghini F, Di Rosa AE, Epifanio A, Grigoletto F, Ragonese P, Patti F, Reggio A, Di Perri R, Savettieri G (2000) Parkinson disease survival: a population-based study. Arch Neurol 57(4):507–512CrossRefPubMed
2.
go back to reference Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2001) Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282CrossRefPubMed Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2001) Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 57(12):2278–2282CrossRefPubMed
4.
go back to reference Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60(1):91–96CrossRefPubMed Elbaz A, Bower JH, Peterson BJ, Maraganore DM, McDonnell SK, Ahlskog JE, Schaid DJ, Rocca WA (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60(1):91–96CrossRefPubMed
8.
go back to reference Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815PubMed Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815PubMed
9.
go back to reference Nakajo S, Omata K, Aiuchi T, Shibayama T, Okahashi I, Ochiai H, Nakai Y, Nakaya K, Nakamura Y (1990) Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem 55(6):2031–2038CrossRefPubMed Nakajo S, Omata K, Aiuchi T, Shibayama T, Okahashi I, Ochiai H, Nakai Y, Nakaya K, Nakamura Y (1990) Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem 55(6):2031–2038CrossRefPubMed
11.
go back to reference Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ (2008) Red blood cells are the major source of α-synuclein in blood. Neurodegener Dis 5(2):55–59. doi:10.1159/000112832 CrossRefPubMed Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, Fox M, Goldstein JM, Soriano F, Seubert P, Chilcote TJ (2008) Red blood cells are the major source of α-synuclein in blood. Neurodegener Dis 5(2):55–59. doi:10.​1159/​000112832 CrossRefPubMed
12.
go back to reference Chen YD, Li X, Yang W, Li X, Yu S (2013) Changes of α-synuclein and its oligomeric formation in plasmas of patients with stroke. J Capital Med Univ 34(6):826–829 Chen YD, Li X, Yang W, Li X, Yu S (2013) Changes of α-synuclein and its oligomeric formation in plasmas of patients with stroke. J Capital Med Univ 34(6):826–829
13.
go back to reference Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, Lule S, Gurer G, Can A, Muller V, Kahle PJ, Dalkara T (2011) Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]α-synuclein transgenic mouse. J Cereb Blood Flow Metab 31(3):913–923. doi:10.1038/jcbfm.2010.170 CrossRefPubMedPubMedCentral Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, Lule S, Gurer G, Can A, Muller V, Kahle PJ, Dalkara T (2011) Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]α-synuclein transgenic mouse. J Cereb Blood Flow Metab 31(3):913–923. doi:10.​1038/​jcbfm.​2010.​170 CrossRefPubMedPubMedCentral
15.
go back to reference Li FFGL, Li X, Feng T (2015) α-synuclein oligomers of red blood cell as a marker for Parkinson’s disease. Chin J Geriatric Heart Brain Vessel Dis 17(2):161–163 Li FFGL, Li X, Feng T (2015) α-synuclein oligomers of red blood cell as a marker for Parkinson’s disease. Chin J Geriatric Heart Brain Vessel Dis 17(2):161–163
16.
go back to reference Chen YDYN, Li X, Yang WW, Li XR, Yu S (2013) The amount change of alpha synuclein and its oligomers in plasma of patients with stroke. J Capital Med Univ 34(6):825–829 Chen YDYN, Li X, Yang WW, Li XR, Yu S (2013) The amount change of alpha synuclein and its oligomers in plasma of patients with stroke. J Capital Med Univ 34(6):825–829
17.
go back to reference Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571–576CrossRefPubMedPubMedCentral Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97(2):571–576CrossRefPubMedPubMedCentral
18.
go back to reference Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416(6880):507–511. doi:10.1038/416507a CrossRefPubMed Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416(6880):507–511. doi:10.​1038/​416507a CrossRefPubMed
19.
go back to reference Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535–539. doi:10.1038/416535a CrossRefPubMed Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535–539. doi:10.​1038/​416535a CrossRefPubMed
20.
go back to reference El-Agnaf OM, Nagala S, Patel BP, Austen BM (2001) Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 310(1):157–168. doi:10.1006/jmbi.2001.4743 CrossRefPubMed El-Agnaf OM, Nagala S, Patel BP, Austen BM (2001) Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 310(1):157–168. doi:10.​1006/​jmbi.​2001.​4743 CrossRefPubMed
21.
go back to reference Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265–1269CrossRefPubMed Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287(5456):1265–1269CrossRefPubMed
22.
25.
go back to reference Kim S, Jeon BS, Heo C, Im PS, Ahn TB, Seo JH, Kim HS, Park CH, Choi SH, Cho SH, Lee WJ, Suh YH (2004) Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J 18(13):1615–1617. doi:10.1096/fj.04-1917fje PubMed Kim S, Jeon BS, Heo C, Im PS, Ahn TB, Seo JH, Kim HS, Park CH, Choi SH, Cho SH, Lee WJ, Suh YH (2004) Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J 18(13):1615–1617. doi:10.​1096/​fj.​04-1917fje PubMed
26.
go back to reference Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20):1766–1772. doi:10.1212/WNL.0b013e3181fd613b CrossRefPubMed Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OM (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20):1766–1772. doi:10.​1212/​WNL.​0b013e3181fd613b​ CrossRefPubMed
28.
go back to reference Withers GS, George JM, Banker GA, Clayton DF (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 99(1):87–94CrossRefPubMed Withers GS, George JM, Banker GA, Clayton DF (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res Dev Brain Res 99(1):87–94CrossRefPubMed
29.
go back to reference Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467–475CrossRefPubMed Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2):467–475CrossRefPubMed
30.
go back to reference Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214–3220PubMed Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214–3220PubMed
31.
go back to reference Kitamura Y, Ishida Y, Takata K, Kakimura J, Mizutani H, Shimohama S, Akaike A, Taniguchi T (2001) Alpha-synuclein protein is not scavenged in neuronal loss induced by kainic acid or focal ischemia. Brain Res 898(1):181–185CrossRefPubMed Kitamura Y, Ishida Y, Takata K, Kakimura J, Mizutani H, Shimohama S, Akaike A, Taniguchi T (2001) Alpha-synuclein protein is not scavenged in neuronal loss induced by kainic acid or focal ischemia. Brain Res 898(1):181–185CrossRefPubMed
32.
go back to reference Chun-song J, Xin L, Yao-hua L, Guang-wei L, Juan-juan Y, Yan-chuan W, Shun Y (2010) Change of α-synuclein level in rat brain and plasma after ischemia/reperfusion. J Capital Med Univ 31(3):368–372 Chun-song J, Xin L, Yao-hua L, Guang-wei L, Juan-juan Y, Yan-chuan W, Shun Y (2010) Change of α-synuclein level in rat brain and plasma after ischemia/reperfusion. J Capital Med Univ 31(3):368–372
33.
go back to reference Chang CY, Lai YC, Cheng TJ, Lau MT, Hu ML (1998) Plasma levels of antioxidant vitamins, selenium, total sulfhydryl groups and oxidative products in ischemic-stroke patients as compared to matched controls in Taiwan. Free Radical Res 28(1):15–24CrossRef Chang CY, Lai YC, Cheng TJ, Lau MT, Hu ML (1998) Plasma levels of antioxidant vitamins, selenium, total sulfhydryl groups and oxidative products in ischemic-stroke patients as compared to matched controls in Taiwan. Free Radical Res 28(1):15–24CrossRef
35.
go back to reference Ishimaru H, Ueda K, Takahashi A, Maruyama Y (1998) Changes in presynaptic protein NACP/α-synuclein in an ischemic gerbil hippocampus. Brain Res 788(1–2):311–314CrossRefPubMed Ishimaru H, Ueda K, Takahashi A, Maruyama Y (1998) Changes in presynaptic protein NACP/α-synuclein in an ischemic gerbil hippocampus. Brain Res 788(1–2):311–314CrossRefPubMed
Metadata
Title
A comparative study of the amount of α-synuclein in ischemic stroke and Parkinson’s disease
Authors
Hui-Qing Zhao
Fang-fei Li
Zhan Wang
Xue-Mei Wang
Tao Feng
Publication date
01-05-2016
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 5/2016
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-016-2485-1

Other articles of this Issue 5/2016

Neurological Sciences 5/2016 Go to the issue